Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.
Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.
Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.
Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.
Emergent BioSolutions (NYSE: EBS) has initiated a Phase 1 study administering stabilized isoamyl nitrite (SIAN) for acute cyanide poisoning treatment. The first participant was dosed on March 11, 2022. This study, funded by BARDA, aims to evaluate SIAN's safety, tolerability, and pharmacokinetics. Targeting 70 healthy participants aged 18-45, SIAN will be developed as an intranasal spray for first responders and civilians. The R&D aligns with Emergent's focus on critical public health threats.
Emergent BioSolutions (EBS) reported Q4 2021 revenues of $723.2 million, a 24% increase from Q4 2020. For FY 2021, total revenues reached $1.79 billion, up 15% year-over-year, while Adjusted EBITDA was $517.6 million (down 18%). The company revised its 2022 guidance downwards, expecting revenues of $1.3 to $1.4 billion due to operational adjustments. Key highlights included a 56% revenue increase in nasal naloxone products and a new supply agreement with Sandoz for an authorized generic of NARCAN. However, net income declined 24% for the year.
Emergent BioSolutions (NYSE: EBS) will hold a conference call on February 24, 2022, at 5:00 PM ET to discuss its fourth-quarter 2021 financial results and business developments. The call will provide insights into the financial outlook for 2022, and revenue guidance for Q1 2022. Interested participants can join via telephone or webcast. Further details regarding the conference call are available on the company's website.
Fuad El-Hibri, founder and executive chairman of Emergent BioSolutions, announced his retirement effective April 1, 2022, after over 20 years of leadership. Under his guidance, the company grew significantly, launching products that address public health threats, including vaccines for anthrax and COVID-19. El-Hibri expressed gratitude to his team for their support and confidence in the company's ongoing strategic goals for 2024. Emergent generated approximately $1.6 billion in revenue in 2020 and will soon announce a new Chair of the Board to succeed El-Hibri.
Emergent BioSolutions reported preliminary 2021 revenues of $1.78 billion, a 14% increase year-over-year, but anticipates a decline in adjusted EBITDA to $512.5 million, down 19%. For 2022, the company projects revenues of $1.45 billion and an adjusted EBITDA margin of 21.5%. The guidance reflects a normalization in CDMO services and the impact of a generic market for NARCAN® Nasal Spray. Additionally, 2022 revenue estimates for key products include $280-$300 million from Anthrax vaccines and $240-$310 million from Nasal Naloxone products.
Emergent BioSolutions (NYSE: EBS) announced participation in three major investor conferences in Q1 2022. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 10-13, with a presentation on January 10 at 8:15 am PST. Following this, the J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference will occur from February 28 to March 2, with a presentation on February 28 at 2:00 pm EST. Lastly, the Cowen & Co. 42nd Annual Health Care Conference will take place March 7-9, with the presentation details to be updated. Webcasts will be accessible live and for replay on the company’s website.
Emergent BioSolutions Inc. (NYSE: EBS) has announced that the first participant has been dosed in its phase 1 study, EBS-UFV-001, which is assessing the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine. The study aims to evaluate the vaccine's effectiveness against influenza A viruses and is taking place in Australia with 60 healthy adults involved. The company emphasizes its commitment to innovative R&D and public health solutions, focusing on a vaccine that could provide broad protection against varying influenza strains.
Emergent BioSolutions (NYSE: EBS) announced a stock repurchase program authorized by its Board of Directors, allowing for the buyback of up to $250 million of its common stock. This initiative, set to expire on November 11, 2022, showcases the company's confidence in its financial stability and growth prospects. As of September 30, 2021, the company held $403.8 million in cash and equivalents, with approximately 53.7 million shares outstanding. The buyback will be executed based on market conditions and is intended to enhance shareholder value.
Emergent BioSolutions reported Q3 2021 financial results with total revenues of $329 million, a 15% decrease from Q3 2020. The net loss was $32.7 million, resulting in a net loss per diluted share of $0.61. Adjusted EBITDA was ($3.3 million). The company secured a $399 million contract modification for AV7909 and initiated a pivotal Phase 3 study for its chikungunya vaccine. A multi-year agreement with Providence Therapeutics is valued at $90 million.
The forecast for 2021 is updated to $1.7 - $1.8 billion in total revenues.
Emergent BioSolutions (NYSE: EBS) will host a conference call on November 4, 2021, at 5:00 PM ET to discuss Q3 2021 financial results, recent developments, and the full-year outlook. Interested parties can join via telephone or webcast. The call will provide insights into the company's financial performance and strategic direction as it aims to enhance public health. For more details, visit the Emergent website.
